W
AVNS

Wealthfront’s Avanos Medical AVNS Stock Holding History

Wealthfront’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-157
Closed -$6K – 1245
2015
Q2 		$6K Sell
157
-9
-5% -$404 ﹤0.01% 983
2015
Q1 		$8K Buy
166
+163
+5,433% +$7.55K ﹤0.01% 669
2014
Q4 		$0 Buy
+3
New +$118 ﹤0.01% 688

Other funds holding AVNS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Shapiro Capital Management Atlanta, Georgia $1.6B AUM 13.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wealthfront's AVNS Position: Q3 2015 in Review

Wealthfront sold out of Avanos Medical (AVNS) in Q3 2015, closing a stake of 157 shares — an estimated $6K sold.

Wealthfront first reported a position in AVNS in Q4 2014 and held it in 3 quarters. The position peaked at $8K in Q1 2015. 353 funds tracked by Wall St. Rank hold AVNS as of Q3 2015.

  • Wealthfront reported no remaining Avanos Medical position as of Q3 2015 after selling out during the quarter.
  • Wealthfront sold 157 Avanos Medical shares in Q3 2015, an estimated $6K.
  • Wealthfront first reported a position in Avanos Medical in Q4 2014 and held it in 3 quarters.
  • Wealthfront's Avanos Medical position peaked at $8K in Q1 2015.
  • 353 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2015.

Based on Wealthfront's 13F filing for Q3 2015, filed 18 Nov 2015.